Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2018-09-25
|
MVX-ONCO-1 |
head and neck squamous cell carcinoma (HNSCC) |
2 |
Maxivax (Switzerland) |
Cancer - Oncology |
2018-09-24
|
AKCEA-APO(a)-LRx |
patients with hyperlipoproteinemia(a) and established cardiovascular disease. |
2b |
Akcea Therapeutics (USA - MA), a subsidiary of Ionis Pharmaceuticals (USA - CA) |
Cardiovascular diseases - Metabolic diseases |
2018-09-24
|
myvacTM |
solid tumors |
preclinical |
Transgene (France) |
Cancer - Oncology |
2018-09-21
|
esketamine |
treatment-resistant depression |
3 |
J&J company (USA - NJ) |
CNS diseases - Mental diseases |
2018-09-20
|
THR-687 |
diabetic macular edema |
1 |
Onxurion (Belgium) |
Ophtalmological diseases |
2018-09-20
|
THR-317 |
macular telangiectasia type 1 (MacTel 1) |
2 |
Oxurion (Belgium) |
Rare diseases - Ophtalmological diseases |
2018-09-19
|
MTL-CEBPA |
advanced liver cancer |
1 |
Mina Therapeutics (UK) |
Cancer - Oncology |
2018-09-15
|
dupilumab |
moderate-to-severe atopic dermatitis |
3 |
Sanofi (France) Regeneron Pharmaceuticals (USA - NY) |
Autoimmune diseases - Dermatological diseases |
2018-09-14
|
Botox® (onabotulinumtoxinA) |
moderate to severe glabellar lines |
|
Allergan (Ireland) |
Aesthetic medicine |
2018-09-14
|
patisiran |
transthyretin-mediated amyloidosis (ATTR) - familial amyloidotic polyneuropathy (FAP) |
3 |
Alnylam Therapeutics (USA - MA) |
Rare diseases - Genetic diseases |
2018-09-13
|
MOR106 |
atopic dermatitis |
1 |
Galapagos (Belgium) Morphosys (Germany) |
Autoimmune diseases - Dermatological diseases |
2018-09-12
|
durvalumab (Imfinzi®) and IPH5401 |
solid tumors, including non small-cell lung cancer (NSCLC) with secondary resistance to prior immuno-oncology (IO) treatment and IO-naïve hepatocarcinoma (HCC) |
1-2 |
Innate Pharma (France) MedImmune (USA - global biologics arm of AstraZeneca (UK) |
Cancer - Oncology |
2018-09-10
|
FPA144 (bemarituzumab) in combination with mFOLFOX6 |
previously untreated, advanced gastric or gastroesophageal cancer |
1-3 |
Five Prime Therapeutics (USA - CA) |
Cancer - Oncology |
2018-09-10
|
Taltz® (ixekizumab) and Tremfya® (guselkumab) |
moderate to severe chronic plaque psoriasis |
4 |
Eli Lilly (USA - IN) |
Autoimmune diseases - Dermatological diseases |
2018-09-10
|
sapacitabin and olaparib |
BRCA mutant breast cancer |
1b-2 |
Cyclacel Pharmaceuticals (USA - NJ) |
Cancer - Oncology |
2018-09-07
|
COM701 |
|
1 |
Compugen (Israel) |
Cancer - Oncology |
2018-09-05
|
SB-913 (adeno-associated virus serotype 2/6 (rAAV2/6) vectors encoding zinc finger nucleases (ZFNs) and the human iduronate 2-sulfatase (hIDS) gene) |
mucopolysaccharidosis type II (MPSII - Hunter's syndrome) |
1-2 |
Sangamo Therapeutics (USA - CA) |
Rare diseases - Genetic diseases |
2018-09-05
|
CYAD-01 - NKR-2 (NKG2D CAR T-Cell) |
colorectal cancer, ovarian Cancer, urothelial carcinoma, triple-negative breast cancer, pancreatic cancer, acute myeloid leukemia/myelodysplastic syndrome, multiple myeloma |
1b |
Celyad (Belgium) |
Cancer - Oncology |
2018-09-05
|
Lenti-D™ |
childhood cerebral adrenoleukodystrophy (CCALD - X-linked adrenoleukodystrophy cerebral childhood) |
2-3 |
Bluebird bio (USA - MA) |
Rare diseases - Genetic diseases - Hematological diseases |
2018-09-05
|
flortaucipir F 18 (LY3303560) |
|
3 |
Eli Lilly (USA - IN) |
|